<h2 dir="ltr">Polycythemia Vera&nbsp;</h2>
Polycythemia Vera is a rare condition characterized by the progressively increased number of red blood cells in the bloodstream, WBC, and platelets also increase in number in the affected people.
<h2 dir="ltr">Symptoms</h2>
<ul>
<li dir="ltr" style="font-weight: bold;" role="presentation"><a href="https://www.delveinsight.com/report-store/fatigue-pipeline-insight">Fatigue</a></li>
<li dir="ltr" role="presentation">Headache</li>
<li dir="ltr" role="presentation">Itching&nbsp;</li>
<li dir="ltr" role="presentation">Trouble in breathing</li>
<li dir="ltr" role="presentation">Mucosal bleeding&nbsp;</li>
<li dir="ltr" style="font-weight: bold;" role="presentation"><a href="https://www.delveinsight.com/report-store/hypertension-epidemiology-forecast">Hypertension</a></li>
<li dir="ltr" role="presentation">Visual disturbance</li>
<li dir="ltr" role="presentation">Bone pain</li>
<li dir="ltr" role="presentation">Dizziness</li>
<li dir="ltr" role="presentation">Numbness</li>
</ul>
<h2 dir="ltr">Diagnosis</h2>
<ul>
<li dir="ltr" role="presentation">Complete blood count&nbsp;</li>
<li dir="ltr" style="font-weight: bold;" role="presentation"><a href="https://www.delveinsight.com/report-store/erythropoietic-protoporphyria-market">Erythropoietin</a></li>
<li dir="ltr" role="presentation">JAK2 Mutation Testing</li>
<li dir="ltr" role="presentation">Bone marrow aspiration</li>
<li dir="ltr" role="presentation">Bone marrow biopsy</li>
</ul>
The diagnosis of polycythemia vera is based on results from tests assessing elevations in blood counts and the presence of molecular mutations associated with the disease. The initial evaluation should include a focused clinical history, physical examination, hematocrit concentration, and count of RBC, WBC, platelets, serum EPO level, and cytogenetic abnormalities.
<h2 dir="ltr">Epidemiology Segmentation</h2>
<ul>
<li dir="ltr" role="presentation">Total Prevalent Population of Polycythemia Vera</li>
<li dir="ltr" role="presentation">Prevalent Population of Polycythemia Vera Based on Symptoms</li>
<li dir="ltr" role="presentation">Gender-specific Prevalence of Polycythemia Vera</li>
<li dir="ltr" role="presentation">Prevalence of Polycythemia Vera by Gene Mutation</li>
<li dir="ltr" role="presentation">Prevalence of Polycythemia Vera Based on Risk</li>
<li dir="ltr" role="presentation">Age-specific Prevalence of Polycythemia Vera</li>
</ul>
<h2 dir="ltr">Epidemiology Insights</h2>
total prevalent cases in the 7MM - 283.5K
US - 56%
EU4 and the UK - 32%
Japan - 12%
Gender-specific Prevalent Cases in the 7MM
Male - 60%
Female - 40%
Prevalent Population Based on Symptoms in the US
Asymptomatic - 40%
Symptomatic - 60%
Prevalent Cases Based on Risk in the 7MM
Low-risk - 10%
High-risk - 90%
Age-specific Prevalent Cases in the US
0&ndash;34 years - 3%
35&ndash;44 years - 8%
45&ndash;54 years - 15%
55&ndash;64 years - 32%
65&ndash;74 years - 22%
75+ years - 20%
96% of patients with polycythemia vera have a mutation of the JAK2 gene
*these figures represent the 2025 data
<h2 dir="ltr">Approved Drugs</h2>
<ul>
<li dir="ltr" role="presentation"><a href="https://www.delveinsight.com/report-store/jakafi-emerging-drug-insight-and-market-forecast">JAKAFI</a>/JAKAVI: Incyte/Novartis</li>
<li dir="ltr" role="presentation"><a href="https://www.delveinsight.com/report-store/besremi-drug-insight-and-market-forecast">BESREMi</a>: PharmaEssentia/AOP Orphan Pharmaceuticals</li>
<li dir="ltr" role="presentation">PEGASYS: pharmaand GmbH</li>
</ul>
The cornerstone of treatment for polycythemia vera remains phlebotomy to maintain safe hematocrit levels, often combined with low-dose aspirin.
Since BESREMi's label is broad (first and subsequent lines of therapy), PharmaEssentia has more leeway in positioning BESREMi in diverse therapeutic situations. Given BESREMi's position upstream of JAKAFI in the NCCN recommendations, the drug is not a direct competitor for JAKAFI. Still, it has the potential to hinder the progression of patients to JAKAFI usage, which might affect JAKAFI's overall revenue.
&ldquo;Currently, there are no effective strategies for reduction in the transformation of PV to myelofibrosis, which can occur in 10&ndash;20% of patients, and transformation to acute myeloid leukemia, which can occur in another 5&ndash;10% of patients. There is a need for treatment options that can decrease the risk of transformation to either myelofibrosis or acute leukemia.&rdquo;
<h2 dir="ltr">Market Insight</h2>
CAGR of 8.9% is predicted for the market during the forecast period (2026-2036)
market size in the 7MM in 2025 - USD 2 billion&nbsp;
US - 78%
EU4 and the UK - 18%
Japan - 4%
The polycythemia vera market is expected to witness significant growth in the coming years, owing to a continuous increase in JAKAFI&rsquo;s usage, early revenue uptake of BESREMI, rusfertide&rsquo;s anticipated launch in 2026, and the expected launch of other emerging therapies during the forecast period of 2026&ndash;2036.&nbsp;
In 2025, among the current therapies for Polycythemia Vera, the largest revenue was generated by JAKAFI, i.e., ~USD 1,000 million in the United States.
<h2 dir="ltr">SWOT Analysis</h2>
<ul>
<li dir="ltr" aria-level="1">
Strengths
</li>
<ul>
<li dir="ltr" aria-level="2">
The approval of BESREMi in the US and its expected approval in Japan, in both the first and second line of treatment, provides the interferon with an immense opportunity to garner a big market size in PV.
</li>
</ul>
<li dir="ltr" aria-level="1">
Weakness
</li>
<ul>
<li dir="ltr" aria-level="2">
The overall cost to treat PV is high, which increases the out-of-pocket cost for patients and poses an economic burden for the patients and their families.
</li>
</ul>
<li dir="ltr" aria-level="1">
Opportunities
</li>
<ul>
<li dir="ltr" aria-level="2">
An increase in strategic alliances, such as geographical alliances, and granting the designation such as BTD and FTD by the FDA are some of the factors that will drive the market growth.
</li>
</ul>
<li dir="ltr" aria-level="1">
Threats
</li>
<ul>
<li dir="ltr" aria-level="2">
If JAKAFI loses the patent before 2028, it will lead to the early entry of ruxolitinib generics as the petitioner still has the right separately to challenge the validity of ruxolitinib patent.
</li>
</ul>
</ul>
<h2 dir="ltr">Emerging Drugs</h2>
By 2036, among all the emerging therapies in the EU4 and the UK, the highest revenue is expected to be generated by Rusfertide.
&nbsp;
<div dir="ltr" align="center">
<table><colgroup><col width="138"><col width="114"><col width="72"><col width="108"></colgroup>
<tbody>
<tr>
<td>
Drug Name
</td>
<td>
Company
</td>
<td>
RoA
</td>
<td>
MoA
</td>
</tr>
<tr>
<td>
Rusfertide (PTG-300)
</td>
<td>
Protagonist Therapeutics and Takeda Pharmaceuticals
</td>
<td>
SC&nbsp;
</td>
<td>
Targeting the underlying mechanism of iron dysregulation
</td>
</tr>
<tr>
<td>
Givinostat (DUVYZAT)
</td>
<td>
Italfarmaco
</td>
<td>
Oral
</td>
<td>
Pan-HDAC inhibitor
</td>
</tr>
<tr>
<td>
Bomedemstat (MK-3543 [IMG-7289])
</td>
<td>
Merck (Imago BioSciences)
</td>
<td>
Oral
</td>
<td>
LSD 1 inhibitor
</td>
</tr>
<tr>
<td>
Sapablursen (IONIS-TMPRSS6-LRx)
</td>
<td>
Ionis Pharmaceuticals and Ono Pharmaceutical
</td>
<td>
SC
</td>
<td>
TMPRSS6 inhibitor
</td>
</tr>
<tr>
<td>
DISC-3405
</td>
<td>
Disc Medicine&rsquo;s
</td>
<td>
SC
</td>
<td>
TMPRSS6 protein inhibitors
</td>
</tr>
<tr>
<td>
Divesiran (SLN124)
</td>
<td>
Silence Therapeutics
</td>
<td>
SC
</td>
<td>
TMPRSS6 inhibitor
</td>
</tr>
<tr>
<td>
PPMX-T003
</td>
<td>
Perseus proteomics
</td>
<td>
IV Infusion
</td>
<td>
TfR1 inhibitors
</td>
</tr>
<tr>
<td>
INCB160058
</td>
<td>
Incyte Corporation
</td>
<td>
Oral
</td>
<td>
JAK 2 inhibitors
</td>
</tr>
<tr>
<td>
GLB-001
</td>
<td>
Hangzhou GluBio Pharmaceutical
</td>
<td>
Oral
</td>
<td>
Casein Kinase 1 Alpha (CK1&alpha;) protein inhibitor
</td>
</tr>
<tr>
<td>
AG-236
</td>
<td>
Agios Pharmaceuticals and Alnylam Pharmaceuticals
</td>
<td>
SC
</td>
<td>
Targeting TMPRSS6
</td>
</tr>
<tr>
<td>
VAC85135
</td>
<td>
Johnson &amp; Johnson Innovative Medicine
</td>
<td>
IM
</td>
<td>
Immunostimulants
</td>
</tr>
<tr>
<td>
Flonoltinib Maleate
</td>
<td>
Chengdu Zenitar Biomedical Technology
</td>
<td>
Oral
</td>
<td>
JAK 2/FMS-like tyrosine kinase 3 (FLT3)&nbsp; inhibitors
</td>
</tr>
<tr>
<td>
JAK2V617F
</td>
<td>
Prelude Therapeutics and Incyte
</td>
<td>
Oral
</td>
<td>
Mutant-Selective Janus Kinase 2 Pseudokinase (JH2) Domain Inhibitors
</td>
</tr>
<tr>
<td>
PN-8047
</td>
<td>
Protagonist Therapeutics&nbsp;
</td>
<td>
Oral
</td>
<td>
Hepcidin mimetic
</td>
</tr>
<tr>
<td>
VGT-1849B
</td>
<td>
Vanda Pharmaceuticals
</td>
<td>
Not disclosed
</td>
<td>
Selectively targeting JAK2 mRNA
</td>
</tr>
<tr>
<td>
VGT-1849A
</td>
<td>
Vanda Pharmaceuticals
</td>
<td>
Not disclosed
</td>
<td>
JAK 2 inhibitors
</td>
</tr>
</tbody>
</table>
</div>
&nbsp;
<h2 dir="ltr">Polycythemia Vera Market: Key Insights</h2>
total prevalent cases in the 7MM in 2025 - 283.5K
CAGR of 8.9% is predicted for the market during the forecast period (2026-2036)
market size in the 7MM in 2025 - USD 2 billion&nbsp;
Report Features - Same
Key Companies: Incyte/Novartis, PharmaEssentia/AOP Orphan Pharmaceuticals, Protagonist Therapeutics, Merck (Imago BioSciences), Italfarmaco, Ionis Pharmaceuticals, Silence Therapeutics, Perseus Proteomics, AbbVie, Johnson &amp; Johnson Innovative Medicine, Mabwell (Shanghai) Bioscience and Disc Medicine
<h2 dir="ltr">Polycythemia Vera Epidemiology Insights</h2>
total prevalent cases in the 7MM - 283.5K
US - 56%
EU4 and the UK - 32%
Japan - 12%
Gender-specific Prevalent Cases in the 7MM
Male - 60%
Female - 40%
Prevalent Population Based on Symptoms in the US
Asymptomatic - 40%
Symptomatic - 60%
Prevalent Cases Based on Risk in the 7MM
Low-risk - 10%
High-risk - 90%
Age-specific Prevalent Cases in the US
0&ndash;34 years - 3%
35&ndash;44 years - 8%
45&ndash;54 years - 15%
55&ndash;64 years - 32%
65&ndash;74 years - 22%
75+ years - 20%
96% of patients with polycythemia vera have a mutation of the JAK2 gene
*these figures represent the 2025 data
<h2 dir="ltr">Polycythemia Vera Market Insight</h2>
CAGR of 8.9% is predicted for the market during the forecast period (2026-2036)
market size in the 7MM in 2025 - USD 2 billion&nbsp;
US - 78%
EU4 and the UK - 18%
Japan - 4%
The polycythemia vera market is expected to witness significant growth in the coming years, owing to a continuous increase in JAKAFI&rsquo;s usage, early revenue uptake of BESREMI, rusfertide&rsquo;s anticipated launch in 2026, and the expected launch of other emerging therapies during the forecast period of 2026&ndash;2036.&nbsp;
In 2025, among the current therapies for Polycythemia Vera, the largest revenue was generated by JAKAFI, i.e., ~USD 1,000 million in the United States.
By 2036, among all the emerging therapies in the EU4 and the UK, the highest revenue is expected to be generated by Rusfertide.

Polycythemia Vera Market Infographics

Polycythemia Vera Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape